Dolutegravir for second-line treatment: Programmatic implications of new evidence

Affiliations

Ying Zhao: Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa; and, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town
Gary Maartens: Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; and, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town
Graeme Meintjes: Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa; and, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town

Abstract

No abstract available.

ISSN: 1608-9693 (Print); 2078-6751 (Online)
Publisher: AOSIS
Country of publisher: South Africa
LCC subjects: Medicine: Public aspects of medicine; Medicine: Internal medicine: Infectious and parasitic diseases
Website: https://sajhivmed.org.za/index.php/hivmed